Clinical Trials Browser

Urinary Bladder Neoplasms × tremelimumab × Clear all

NCT03682068 2026-02-03

NILE

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04960709 2025-12-19

VOLGA

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03601455 2025-04-13

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT03317158 2025-01-30

ADAPT-BLADDER

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05120622 2023-10-31

Rideau

Phase 1/2 Withdrawn

Urinary Bladder Neoplasms

NCT03472274 2023-04-13

DUTRENEO

Phase 2 Completed

Urinary Bladder Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Phase 1/2 Completed

58 enrolled 24 charts

BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT03430895 2021-12-01

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Phase 2 Completed

15 enrolled 8 charts

Urinary Bladder Neoplasms

NCT04073160 2020-07-07

TRIO Bladder

Phase 1 Withdrawn

Urinary Bladder Neoplasms

NCT00880854 2019-11-15

Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer

Phase 1 Withdrawn

Urinary Bladder Neoplasms